Plasma BNP as a Biomarker for Clinical Staging of Heart Failure.
Loading...
Date
2010
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Background: Accurate diagnosis and clinical staging of heart failure (HF) is essential for its proper
management and logical drug therapy to reduce morbidity and mortality. On this perspective
researcher are in search of a good biomarker as complementary to the clinical parameters to improve
the performance of HF diagnosis and its clinical staging. B-type natriuretic peptide (BNP) secreted
by cardiac ventricles in HF has emerged as a new promising biomarker in this regard. Objective of
the study was evaluation of plasma BNP concentration in relation to the severity of HF and its use
as a biomarker for clinical staging of HF.
Methods: In a cross sectional study 100 HF cases diagnosed by clinical parameters and
echocardiography were enrolled and sub grouped into NYHA classes (I, II, II & IV) depending on
clinical severity and functional limitations. Plasma BNP measured in all study subjects and
summarized in each of these sub groups.
Results: Median plasma BNP concentration in NYHA class-I, II, III & IV found to be 82.7, 267.2,
694.8 & 1530.4pg/ml respectively with progressive rising trend and at 95% CI level the plasma BNP
in different sub groups were 64.5-112.7, 214.3-293.5, 626.4-902.4 & 1443.1-2384.4pg/ml respectively.
Conclusion: Plasma BNP concentration increases progressively with increasing severity of HF to
make it to be used for clinical staging of the disease. In mild, moderate and severe HF plasma BNP
proposed to be 100-460, 460-1170 and >1170pg/ml respectively.
Description
Keywords
BNP, Heart failure, Biomarker
Citation
Hoque M M, Shafiullah S, Sultana P. Plasma BNP as a Biomarker for Clinical Staging of Heart Failure. Cardiovascular Journal. 2010; 2(2): 142-146.